Lucid Diagnostics Inc (LUCD) - Total Assets
Based on the latest financial reports, Lucid Diagnostics Inc (LUCD) holds total assets worth $40.45 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore LUCD operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Lucid Diagnostics Inc - Total Assets Trend (2018–2025)
This chart illustrates how Lucid Diagnostics Inc's total assets have evolved over time, based on quarterly financial data. See what is Lucid Diagnostics Inc's book value for net asset value and shareholders' equity analysis.
Lucid Diagnostics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Lucid Diagnostics Inc's total assets of $40.45 Million consist of 92.6% current assets and 7.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 85807.9% |
| Accounts Receivable | $643.00K | 1.6% |
| Inventory | $353.00 Million | 872.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $315.00 Million | 778.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Lucid Diagnostics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Lucid Diagnostics Inc (LUCD) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lucid Diagnostics Inc's current assets represent 92.6% of total assets in 2025, a decrease from 100.0% in 2018.
- Cash Position: Cash and equivalents constituted 85807.9% of total assets in 2025, up from 100.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 778.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is inventory at 872.8% of total assets.
Lucid Diagnostics Inc Competitors by Total Assets
Key competitors of Lucid Diagnostics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Bio-Rad Laboratories Inc
NYSE:BIO
|
USA | $9.79 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
Tellgen Corp
SHE:300642
|
China | CN¥2.01 Billion |
|
Affluent Medical SAS
PA:AFME
|
France | €59.84 Million |
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
4DMEDICAL Ltd
AU:4DX
|
Australia | AU$139.55 Million |
|
Anteris Technologies Global Corp
AU:AVR
|
Australia | AU$19.07 Million |
|
Imricor Medical Systems Inc
AU:IMR
|
Australia | AU$45.79 Million |
Lucid Diagnostics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.31 | 1.07 | 0.07 |
| Quick Ratio | -11.04 | 1.05 | 0.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $8.89 Million | $1.62 Million | $-17.13 Million |
Lucid Diagnostics Inc - Advanced Valuation Insights
This section examines the relationship between Lucid Diagnostics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.16 |
| Latest Market Cap to Assets Ratio | 4.21 |
| Asset Growth Rate (YoY) | 31.7% |
| Total Assets | $40.45 Million |
| Market Capitalization | $170.18 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Lucid Diagnostics Inc's assets at a significant premium (4.21x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Lucid Diagnostics Inc's assets grew by 31.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Lucid Diagnostics Inc (2018–2025)
The table below shows the annual total assets of Lucid Diagnostics Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $40.45 Million | +31.68% |
| 2024-12-31 | $30.71 Million | +12.63% |
| 2023-12-31 | $27.27 Million | -16.12% |
| 2022-12-31 | $32.51 Million | -44.90% |
| 2021-12-31 | $59.00 Million | +2587.88% |
| 2020-12-31 | $2.19 Million | +112.30% |
| 2019-12-31 | $1.03 Million | +5708.43% |
| 2018-12-31 | $17.80K | -- |
About Lucid Diagnostics Inc
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with th… Read more